You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 121 No. 11, November 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE 39TH ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, WASHINGTON, DC, MAY 12 TO MAY 14, 1986-PART I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (33)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Multimodal Therapy for Locally Advanced Breast Cancer

Monica Morrow, MD; Albert Braverman, MD; William Thelmo, MD; Chul K. Sohn, MD; Julian Sand, MD; Maximo Mora, MD; Thomas Forlenza, MD; Jose Marti, MD

Arch Surg. 1986;121(11):1291-1296.


Abstract

• Thirty-one women with stage III breast cancer were prospectively treated with two cycles of cyclophosphamide (Cytoxan), doxorubicin hydrochloride (Adriamycin), fluorouracil, and tamoxifen citrate followed by a simple mastectomy with level I axillary dissection. Postoperatively, four additional cycles of the combination chemotherapy alternating with three cycles of 1500 rad (15 Gy) to the chest wall and lymphatics were given. Seventy-seven percent of patients had a greater than 50% reduction in tumor size after the initial chemotherapy. No tumor size progressed during therapy, and a single patient remained inoperable. Pathologic findings revealed nine patients with only microscopic residual tumor. Nuclear vacuolization was present in 42.8% of tumor cells after chemotherapy vs 14.2% of cells before chemotherapy. The mean follow-up for the groups is 24.3 months. To date, nine patients have had recurrence with only one isolated local recurrence. This therapy is effective in reducing primary tumor size and allows a limited mastectomy to be done with minimal morbidity.

(Arch Surg 1986;121:1291-1296)



Author Affiliations

From the Departments of Surgery (Drs Morrow and Marti), Medical Oncology (Drs Braverman, Sand, and Forlenza), Pathology (Drs Thelmo and Mora), and Radiation Therapy (Dr Sohn), State University of New York—Health Science Center at Brooklyn.


Footnotes

Accepted for publication Aug 5, 1986.

Read before the 39th Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 13, 1986.

Reprint requests to 450 Clarkson Ave, Box 40, Brooklyn, NY 11203 (Dr Morrow).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Multimodal-Therapy Breast Salvage in the Urban Poor With Locally Advanced Cancer
Boddie et al.
Arch Surg 1996;131:424-428.
ABSTRACT  

Neoadjuvant Chemotherapy Before Definitive Treatment for Stage III Carcinoma of the Breast
Schwartz et al.
Arch Surg 1987;122:1430-1434.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.